Business & Finance
JHL Biotech submits clinical trial application to Bulgarian Drug Agency for proposed bevacizumab biosimilar for multiple cancers
21 December 2017 -

Biopharmaceutical startup JHL Biotech Inc (Stock Code:6540.TWO) disclosed on Wednesday the submission of its Phase I Clinical Trial Application to European authorities (Bulgarian Drug Agency) for its proposed bevacizumab biosimilar, JHL1149, for the treatment of many cancers.

According to the company, JHL1149 would provide an affordable alternative to bevacizumab, a biologic used for the treatment of many cancers, the most common of which are metastatic colorectal cancer, lung cancer and ovarian cancer. In 2016, bevacizumab generated revenues of approximately USD7bn.

In conjunction with the submission of its application in Europe, the company is planning to launch a single-site, three-arm pharmacokinetic study in healthy volunteers in Sofia, Bulgaria beginning March 2018.

The company concluded the data from this planned trial will support the rapid development and commercialisation of JHL1149.